Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended Thursday session in red amid volatile trading. The shares closed down -0.15 points or -1.45% at $10.19 with 2.55 million shares getting traded. Post opening the session at $10.33, the shares hit an intraday low of $10.06 and an intraday high of $10.37 and the price vacillated in this range throughout the day. The company has a market cap of $1.95 billion and the numbers of outstanding shares have been calculated to be 192.71 million shares.
Ariad Pharmaceuticals, Inc. (ARIA) on August 30, 2016 announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the U.S. Food and Drug Administration (FDA). ARIAD is seeking U.S. marketing approval of brigatinib for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. The Company is seeking accelerated approval for brigatinib from the FDA and has requested a priority review of the application, which, if granted, would allow for approval of brigatinib eight months after the NDA submission, as opposed to 12 months for a standard review.
“Many patients with ALK-positive non-small cell lung cancer eventually develop disease progression,” said Corey Langer, M.D., director of thoracic oncology in the Abramson Cancer Center of the University of Pennsylvania and a professor of Hematology-Oncology in Penn’s Perelman School of Medicine. “We are excited that the brigatinib NDA submission is now complete and are hopeful that brigatinib’s data, including the observation of complete responses and activity in the central nervous system, will provide patients and their oncologists with a new treatment option.”
Shares of Allergan plc Ordinary Shares (NYSE:AGN) ended Thursday session in green amid volatile trading. The shares closed up +3.22 points or 1.37% at $237.76 with 2.83 million shares getting traded. Post opening the session at $235.22, the shares hit an intraday low of $233.62 and an intraday high of $238.40 and the price vacillated in this range throughout the day. The company has a market cap of $92.87 billion and the numbers of outstanding shares have been calculated to be 395.95 million shares.
Allergan plc Ordinary Shares (AGN) announced that Brent Saunders, Allergan’s CEO and President, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 11:45 a.m. ET at the Grand Hyatt in New York, NY.
The presentation will be webcast live and can be accessed on Allergan’s Investor Relations web site at http://ir.allergan.com.
An archived version will be available approximately two hours after the live presentation ends and can be accessed at the same locations for 180 days.